Elevated serum IL-17 A and CCL20 levels as potential biomarkers in major psychotic disorders: a case-control study.
CCL20
IL-17A
Major psychotic disorders
PANSS
Schizoaffective disorder
Schizophrenia
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
11 Oct 2024
11 Oct 2024
Historique:
received:
22
03
2024
accepted:
20
08
2024
medline:
12
10
2024
pubmed:
12
10
2024
entrez:
11
10
2024
Statut:
epublish
Résumé
Major psychotic disorders (MPD), including schizophrenia (SCZ) and schizoaffective disorder (SAD), are severe neuropsychiatric conditions with unclear causes. Understanding their pathophysiology is essential for better diagnosis, treatment, and prognosis. Recent research highlights the role of inflammation and the immune system, particularly the Interleukin 17 (IL-17) family, in these disorders. Elevated IL-17 levels have been found in MPD, and human IL-17 A antibodies are available. Changes in chemokine levels, such as CCL20, are also noted in SCZ. This study investigates the relationship between serum levels of IL-17 A and CCL20 in MPD patients and their clinical characteristics. We conducted a case-control study at the Ibn Sina Psychiatric Hospital (Mashhad, Iran) in 2023. The study involved 101 participants, of which 71 were MPD patients and 30 were healthy controls (HC). The Positive and Negative Symptom Scale (PANSS) was utilized to assess the symptoms of MPD patients. Serum levels of CCL20 and IL-17 A were measured using Enzyme-Linked Immunosorbent Assay (ELISA) kits. We also gathered data on lipid profiles and Fasting Blood Glucose (FBS). The mean age of patients was 41.04 ± 9.93 years. The median serum levels of CCL20 and IL-17 A were significantly elevated in MPD patients compared to HC (5.8 (4.1-15.3) pg/mL and 4.2 (3-5) pg/mL, respectively; p < 0.001). Furthermore, CCL20 and IL-17 A levels showed a positive correlation with the severity of MPD. MPD patients also had significantly higher FBS, cholesterol, and Low-Density Lipoprotein (LDL) levels, and lower High-Density Lipoprotein (HDL) levels compared to HC. No significant relationship was found between PANSS components and blood levels of IL17 and CCL20. The current study revealed that the serum levels of IL-17 A and CCL20 in schizophrenia patients are higher than those in the control group. Metabolic factors such as FBS, cholesterol, HDL, and LDL also showed significant differences between MPD and HC. In conclusion, the findings suggest that these two inflammatory factors could serve as potential therapeutic targets and prognostic biomarkers for schizophrenia.
Sections du résumé
BACKGROUND
BACKGROUND
Major psychotic disorders (MPD), including schizophrenia (SCZ) and schizoaffective disorder (SAD), are severe neuropsychiatric conditions with unclear causes. Understanding their pathophysiology is essential for better diagnosis, treatment, and prognosis. Recent research highlights the role of inflammation and the immune system, particularly the Interleukin 17 (IL-17) family, in these disorders. Elevated IL-17 levels have been found in MPD, and human IL-17 A antibodies are available. Changes in chemokine levels, such as CCL20, are also noted in SCZ. This study investigates the relationship between serum levels of IL-17 A and CCL20 in MPD patients and their clinical characteristics.
METHOD
METHODS
We conducted a case-control study at the Ibn Sina Psychiatric Hospital (Mashhad, Iran) in 2023. The study involved 101 participants, of which 71 were MPD patients and 30 were healthy controls (HC). The Positive and Negative Symptom Scale (PANSS) was utilized to assess the symptoms of MPD patients. Serum levels of CCL20 and IL-17 A were measured using Enzyme-Linked Immunosorbent Assay (ELISA) kits. We also gathered data on lipid profiles and Fasting Blood Glucose (FBS).
RESULTS
RESULTS
The mean age of patients was 41.04 ± 9.93 years. The median serum levels of CCL20 and IL-17 A were significantly elevated in MPD patients compared to HC (5.8 (4.1-15.3) pg/mL and 4.2 (3-5) pg/mL, respectively; p < 0.001). Furthermore, CCL20 and IL-17 A levels showed a positive correlation with the severity of MPD. MPD patients also had significantly higher FBS, cholesterol, and Low-Density Lipoprotein (LDL) levels, and lower High-Density Lipoprotein (HDL) levels compared to HC. No significant relationship was found between PANSS components and blood levels of IL17 and CCL20.
CONCLUSION
CONCLUSIONS
The current study revealed that the serum levels of IL-17 A and CCL20 in schizophrenia patients are higher than those in the control group. Metabolic factors such as FBS, cholesterol, HDL, and LDL also showed significant differences between MPD and HC. In conclusion, the findings suggest that these two inflammatory factors could serve as potential therapeutic targets and prognostic biomarkers for schizophrenia.
Identifiants
pubmed: 39394574
doi: 10.1186/s12888-024-06032-3
pii: 10.1186/s12888-024-06032-3
doi:
Substances chimiques
Interleukin-17
0
Chemokine CCL20
0
Biomarkers
0
CCL20 protein, human
0
IL17A protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
677Informations de copyright
© 2024. The Author(s).
Références
James SL, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet. 2018;392(10159):1789–858.
doi: 10.1016/S0140-6736(18)32279-7
Shojaeimotlagh V, et al. Prevalence of metabolic syndrome in Iranian patients with schizophrenia: a systematic review and meta-analysis. Volume 13. Diabetes & Metabolic Syndrome: Clinical Research & Reviews; 2019. pp. 143–7. 1.
Mohammadi M-R, et al. An epidemiological survey of psychiatric disorders in Iran. Clin Pract Epidemiol Mental Health. 2005;1:1–8.
doi: 10.1186/1745-0179-1-16
Petrova N, et al. Clinical and immunological profile of patients with schizophrenia. Eur Psychiatry. 2022;65(S1):S105–6.
pmcid: 9565172
doi: 10.1192/j.eurpsy.2022.301
Lang FU, et al. Subtyping schizophrenia: a comparison of positive/negative and system-specific approaches. Compr Psychiatr. 2015;61:115–21.
doi: 10.1016/j.comppsych.2015.05.014
Bosia M, et al. From cognitive and clinical substrates to functional profiles: disentangling heterogeneity in schizophrenia. Psychiatry Res. 2019;271:446–53.
pubmed: 30537667
doi: 10.1016/j.psychres.2018.12.026
Rodrigues-Amorim D, et al. Cytokines dysregulation in schizophrenia: a systematic review of psychoneuroimmune relationship. Schizophr Res. 2018;197:19–33.
pubmed: 29239785
doi: 10.1016/j.schres.2017.11.023
Roomruangwong C, et al. The role of aberrations in the immune-inflammatory response system (IRS) and the compensatory immune-regulatory reflex system (CIRS) in different phenotypes of schizophrenia: the IRS-CIRS theory of schizophrenia. Mol Neurobiol. 2020;57:778–97.
pubmed: 31473906
doi: 10.1007/s12035-019-01737-z
Najjar S, Pearlman DM. Neuroinflammation and white matter pathology in schizophrenia: systematic review. Schizophr Res. 2015;161(1):102–12.
pubmed: 24948485
doi: 10.1016/j.schres.2014.04.041
Ouyang L, et al. IL-17 and TNF-β: predictive biomarkers for transition to psychosis in ultra-high risk individuals. Front Psychiatry. 2022;13:1072380.
pubmed: 36590607
pmcid: 9800867
doi: 10.3389/fpsyt.2022.1072380
Al-Hakeim HK, et al. The interleukin-6/interleukin-23/T helper 17-axis as a driver of neuro-immune toxicity in the major neurocognitive psychosis or deficit schizophrenia: a precision nomothetic psychiatry analysis. PLoS ONE. 2022;17(10):e0275839.
pubmed: 36256663
pmcid: 9578624
doi: 10.1371/journal.pone.0275839
Al-Musawi AF, et al. In schizophrenia, the effects of the IL-6/IL-23/Th17 axis on health-related quality of life and disabilities are partly mediated by generalized cognitive decline and the symptomatome. Int J Environ Res Public Health. 2022;19(22):15281.
pubmed: 36429996
pmcid: 9690590
doi: 10.3390/ijerph192215281
Toussirot É. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy-Drug Targets (Formerly Curr Drug Targets-Inflammation Allergy)(Discontinued). 2012;11(2):159–68.
Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family. J Leukoc Biol. 2002;71(1):1–8.
pubmed: 11781375
doi: 10.1189/jlb.71.1.1
Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009;9(8):556–67.
pubmed: 19575028
pmcid: 2821718
doi: 10.1038/nri2586
Fossiez F, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med. 1996;183(6):2593–603.
pubmed: 8676080
doi: 10.1084/jem.183.6.2593
Korn T, et al. IL-17 and Th17 cells. Annu Rev Immunol. 2009;27:485–517.
pubmed: 19132915
doi: 10.1146/annurev.immunol.021908.132710
Park H, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6(11):1133–41.
pubmed: 16200068
pmcid: 1618871
doi: 10.1038/ni1261
Zimmermann J, et al. CNS-targeted production of IL-17A induces glial activation, microvascular pathology and enhances the neuroinflammatory response to systemic endotoxemia. PLoS ONE. 2013;8(2):e57307.
pubmed: 23468966
pmcid: 3584143
doi: 10.1371/journal.pone.0057307
Silfvast-Kaiser A, Paek SY, Menter A. Anti-IL17 therapies for psoriasis. Expert Opin Biol Ther. 2019;19(1):45–54.
pubmed: 30500317
doi: 10.1080/14712598.2019.1555235
Chandrakumar SF, Yeung J. Interleukin-17 antagonists in the treatment of psoriasis. J Cutan Med Surg. 2015;19(2):109–14.
pubmed: 25775627
doi: 10.2310/7750.2014.14038
Liu Y, HO RCM, Mak A. The role of interleukin (IL)-17 in anxiety and depression of patients with rheumatoid arthritis. Int J Rheum Dis. 2012;15(2):183–7.
pubmed: 22462422
doi: 10.1111/j.1756-185X.2011.01673.x
Chen Y, et al. Emerging tendency towards autoimmune process in major depressive patients: a novel insight from Th17 cells. Psychiatry Res. 2011;188(2):224–30.
pubmed: 21129782
doi: 10.1016/j.psychres.2010.10.029
Barbosa IG, et al. The immunology of bipolar disorder. Neuroimmunomodulation. 2014;21(2–3):117–22.
pubmed: 24557044
doi: 10.1159/000356539
Axtell RC, Steinman L. Gaining entry to an uninflamed brain. Nat Immunol. 2009;10(5):453–5.
pubmed: 19381137
doi: 10.1038/ni0509-453
Yamazaki T, et al. CCR6 regulates the migration of inflammatory and regulatory T cells. J Immunol. 2008;181(12):8391–401.
pubmed: 19050256
doi: 10.4049/jimmunol.181.12.8391
Shen F, Gaffen SL. Structure–function relationships in the IL-17 receptor: implications for signal transduction and therapy. Cytokine. 2008;41(2):92–104.
pubmed: 18178098
pmcid: 2667118
doi: 10.1016/j.cyto.2007.11.013
Ogura H, et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity. 2008;29(4):628–36.
pubmed: 18848474
doi: 10.1016/j.immuni.2008.07.018
Lee AY, et al. CC chemokine ligand 20 and its cognate receptor CCR6 in mucosal T cell immunology and inflammatory bowel disease: odd couple or axis of evil? Front Immunol. 2013;4:194.
pubmed: 23874340
pmcid: 3711275
doi: 10.3389/fimmu.2013.00194
Tandon P, et al. Metabolic regulation of inflammation and its resolution: current status, clinical needs, challenges, and opportunities. J Immunol. 2021;207(11):2625–30.
pubmed: 34810268
doi: 10.4049/jimmunol.2100829
Papanastasiou E. The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review. Therapeutic Adv Psychopharmacol. 2013;3(1):33–51.
doi: 10.1177/2045125312464385
Padmavati R, McCreadie RG, Tirupati S. Low prevalence of obesity and metabolic syndrome in never-treated chronic schizophrenia. Schizophr Res. 2010;121(1–3):199–202.
pubmed: 20538429
doi: 10.1016/j.schres.2010.05.010
Tirupati S, Chua L-E. Obesity and metabolic syndrome in a psychiatric rehabilitation service. Australian New Z J Psychiatry. 2007;41(7):606–10.
doi: 10.1080/00048670701392841
Young RC, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133(5):429–35.
pubmed: 728692
doi: 10.1192/bjp.133.5.429
Shahini N, et al. Relationship of serum homocysteine and vitamin D with positive, negative, and extrapyramidal symptoms in schizophrenia: a case–control study in Iran. BMC Psychiatry. 2022;22(1):681.
pubmed: 36333678
pmcid: 9635078
doi: 10.1186/s12888-022-04246-x
Noto MN, et al. Activation of the immune-inflammatory response system and the compensatory immune-regulatory system in antipsychotic naive first episode psychosis. Eur Neuropsychopharmacol. 2019;29(3):416–31.
pubmed: 30594344
doi: 10.1016/j.euroneuro.2018.12.008
Wallwork R, et al. Searching for a consensus five-factor model of the positive and negative syndrome scale for schizophrenia. Schizophr Res. 2012;137(1–3):246–50.
pubmed: 22356801
pmcid: 3351536
doi: 10.1016/j.schres.2012.01.031
Miller BJ, et al. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70(7):663–71.
pubmed: 21641581
pmcid: 4071300
doi: 10.1016/j.biopsych.2011.04.013
Upthegrove R, Barnes NM. The immune system and schizophrenia: an update for clinicians. Adv Psychiatr Treat. 2014;20(2):83–91.
doi: 10.1192/apt.bp.113.011452
Smith R, Maes M. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med Hypotheses. 1995;45(2):135–41.
pubmed: 8531836
doi: 10.1016/0306-9877(95)90062-4
Pantelis C, et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421–7.
pmcid: 4112379
doi: 10.1038/nature13595
Bennett F, Molofsky A. The immune system and psychiatric disease: a basic science perspective. Clin Experimental Immunol. 2019;197(3):294–307.
doi: 10.1111/cei.13334
Wilson NJ, et al. Development, cytokine profile and function of human interleukin 17–producing helper T cells. Nat Immunol. 2007;8(9):950–7.
pubmed: 17676044
doi: 10.1038/ni1497
Louten J, Boniface K, de Waal Malefyt R. Development and function of TH17 cells in health and disease. J Allergy Clin Immunol. 2009;123(5):1004–11.
pubmed: 19410689
doi: 10.1016/j.jaci.2009.04.003
Kelly MN, et al. Interleukin-17/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against Toxoplasma Gondii infection. Infect Immun. 2005;73(1):617–21.
pubmed: 15618203
pmcid: 538931
doi: 10.1128/IAI.73.1.617-621.2005
Eyerich K, et al. Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22. J Invest Dermatology. 2008;128(11):2640–5.
doi: 10.1038/jid.2008.139
Romagnani S. Human Th17 cells. Arthritis Res Therapy. 2008;10:1–8.
doi: 10.1186/ar2392
Milovanovic J, et al. Interleukin-17 in chronic inflammatory neurological diseases. Front Immunol. 2020;11:947.
pubmed: 32582147
pmcid: 7283538
doi: 10.3389/fimmu.2020.00947
Lu Y, et al. Advances in the study of IL-17 in neurological diseases and mental disorders. Front Neurol. 2023;14:1284304.
pubmed: 38046578
pmcid: 10690603
doi: 10.3389/fneur.2023.1284304
Mills KH. IL-17 and IL-17-producing cells in protection versus pathology. Nat Rev Immunol. 2023;23(1):38–54.
pubmed: 35790881
doi: 10.1038/s41577-022-00746-9
León-Ortiz P, et al. Systemic inflammation and cortical neurochemistry in never-medicated first episode-psychosis individuals. Brain Behav Immun. 2023;111:270–6.
pubmed: 37149107
pmcid: 10330452
doi: 10.1016/j.bbi.2023.05.001
Saeki K, et al. A major lipid raft protein raftlin modulates T cell receptor signaling and enhances th17-mediated autoimmune responses. J Immunol. 2009;182(10):5929–37.
pubmed: 19414744
doi: 10.4049/jimmunol.0802672
Hurşitoğlu O et al. Serum NOX1 and raftlin as new potential biomarkers of interest in schizophrenia: a preliminary study. Neuropsychiatr Dis Treat, 2022: p. 2519–27.
Ding M, et al. Activation of Th17 cells in drug naïve, first episode schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2014;51:78–82.
pubmed: 24447943
doi: 10.1016/j.pnpbp.2014.01.001
Mazrakhondi SAM, Zare-Zardini H. Comparison of serum changes of Interleukin-17A and Interleukin-21 between schizophrenic patients and healthy individuals. Volume 11. Reports of Biochemistry & Molecular Biology; 2022. p. 465. 3.
Dunleavy C et al. Inflammation in first-episode psychosis. 2022.
Kale A, et al. Immune-mediated inflammatory markers in acute and transient psychotic disorders—comparison with schizophrenia: an exploratory comparative study. Early Interv Psychiat. 2023;17(2):183–91.
doi: 10.1111/eip.13319
Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity. 2012;36(5):705–16.
pubmed: 22633458
pmcid: 3396424
doi: 10.1016/j.immuni.2012.05.008
Stuart M, Baune B. Chemokines and chemokine receptors in mood disorders, schizophrenia, and cognitive impairment: a systematic review of biomarker studies. Neurosci Biobehavioral Reviews. 2014;42:93–115.
doi: 10.1016/j.neubiorev.2014.02.001
Akkouh IA, et al. Decreased IL-1β-induced CCL20 response in human iPSC-astrocytes in schizophrenia: potential attenuating effects on recruitment of regulatory T cells. Brain Behav Immun. 2020;87:634–44.
pubmed: 32109548
doi: 10.1016/j.bbi.2020.02.008
Lee AY, Körner H. The CCR6-CCL20 axis in humoral immunity and TB cell immunobiology. Immunobiology. 2019;224(3):449–54.
pubmed: 30772094
doi: 10.1016/j.imbio.2019.01.005
Duan F, et al. Changes of immune-related factors in the blood of schizophrenia and bipolar disorder patients receiving monotherapy. Translational Psychiatry. 2022;12(1):212.
pubmed: 35618730
pmcid: 9135722
doi: 10.1038/s41398-022-01968-0
Cathomas F, et al. Increased random exploration in schizophrenia is associated with inflammation. Npj Schizophrenia. 2021;7(1):6.
pubmed: 33536449
pmcid: 7859392
doi: 10.1038/s41537-020-00133-0
Dahan S, et al. The relationship between serum cytokine levels and degree of psychosis in patients with schizophrenia. Psychiatry Res. 2018;268:467–72.
pubmed: 30138859
doi: 10.1016/j.psychres.2018.07.041
Szymona K, et al. Correlations of kynurenic acid, 3-hydroxykynurenine, sIL-2R, IFN-α, and IL-4 with clinical symptoms during acute relapse of schizophrenia. Neurotox Res. 2017;32:17–26.
pubmed: 28275903
doi: 10.1007/s12640-017-9714-0
Momtazmanesh S, Zare-Shahabadi A, Rezaei N. Cytokine alterations in schizophrenia: an updated review. Front Psychiatry. 2019;10:496638.
doi: 10.3389/fpsyt.2019.00892
Carney R, et al. Cardiometabolic risk factors in young people at ultra-high risk for psychosis: a systematic review and meta-analysis. Schizophr Res. 2016;170(2–3):290–300.
pubmed: 26794596
doi: 10.1016/j.schres.2016.01.010
Penninx BW, Lange SM. Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. Dialog Clin Neurosci. 2018;20(1):63–73.
doi: 10.31887/DCNS.2018.20.1/bpenninx
Rojo LE, et al. Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology. Pharmacol Res. 2015;101:74–85.
pubmed: 26218604
doi: 10.1016/j.phrs.2015.07.022
Pillinger T, et al. Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry. 2017;74(3):261–9.
pubmed: 28097367
pmcid: 6352957
doi: 10.1001/jamapsychiatry.2016.3803
Halle M, et al. Importance of TNF-alpha and leptin in obesity and insulin resistance: a hypothesis on the impact of physical exercise. Exerc Immunol Rev. 1998;4:77–94.
pubmed: 9644096
Leonard BE, Schwarz M, Myint AM. The metabolic syndrome in schizophrenia: is inflammation a contributing cause? J Psychopharmacol. 2012;26(5suppl):33–41.
pubmed: 22472311
doi: 10.1177/0269881111431622
Jin H, et al. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res. 2008;100(1–3):70–85.
pubmed: 18206351
pmcid: 2699769
doi: 10.1016/j.schres.2007.11.026
Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2004;66(1):51–7.
pubmed: 14693352
doi: 10.1016/S0920-9964(02)00498-X
Saccaro LF, et al. Shared and unique characteristics of metabolic syndrome in psychotic disorders: a review. Front Psychiatry. 2024;15:1343427.
pubmed: 38501085
pmcid: 10944869
doi: 10.3389/fpsyt.2024.1343427
Gurusamy J, et al. Effect of lifestyle modification intervention (LMI) on metabolic syndrome in schizophrenia in a residential mental health care setting–A mixed method study. Schizophr Res. 2024;266:75–84.
pubmed: 38377870
doi: 10.1016/j.schres.2024.02.002
Borovcanin MM, et al. Type 17 immune response facilitates progression of inflammation and correlates with cognition in stable schizophrenia. Diagnostics. 2020;10(11):926.
pubmed: 33182582
pmcid: 7698203
doi: 10.3390/diagnostics10110926
Chenniappan R, et al. Interleukin-17 and interleukin-10 association with disease progression in schizophrenia. Annals Neurosciences. 2020;27(1):24–8.
doi: 10.1177/0972753120929565
Dimitrov DH, et al. Differential correlations between inflammatory cytokines and psychopathology in veterans with schizophrenia: potential role for IL-17 pathway. Schizophr Res. 2013;151(1–3):29–35.
pubmed: 24210870
doi: 10.1016/j.schres.2013.10.019
Göteson A, et al. A serum proteomic study of two case-control cohorts identifies novel biomarkers for bipolar disorder. Translational Psychiatry. 2022;12(1):55.
pubmed: 35136035
pmcid: 8826439
doi: 10.1038/s41398-022-01819-y
Luger D, et al. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med. 2008;205(4):799–810.
pubmed: 18391061
pmcid: 2292220
doi: 10.1084/jem.20071258